Aleksander Chojecki, Danielle Boselli, Allison Dortilus, Issam Hamadeh, Stephanie Begley, Tommy Chen, Rupali Bose, Nikolai Podoltsev, Amer M Zeidan, Nicole Baranda Balmaceda, Abdulraheem Yacoub, Jing Ai, Thomas Gregory Knight, Brittany Knick Ragon, Nilay Arvind Shah, Srinivasa Reddy Sanikommu, James Symanowski, Ruben Mesa, Michael Richard Grunwald
Polycythemia vera (PV) is a myeloproliferative neoplasm characterized by unregulated red blood cell production resulting in elevated hemoglobin and/or hematocrit levels. Patients often have symptoms such as fatigue, pruritus, and painful splenomegaly, but are also at risk of thrombosis, both venous and arterial. Ruxolitinib, a selective Janus kinase inhibitor, is approved by the US Food and Drug Administration as second-line cytoreductive treatment after intolerance or inadequate response to hydroxyurea. Although ruxolitinib has been widely used in this setting, limited data exist in the literature on ruxolitinib treatment patterns and outcomes among patients with PV in routine clinical practice...
April 25, 2024: Annals of Hematology